Connor, Clark & Lunn Investment Management (CC&L)
SEEL

Connor, Clark & Lunn Investment Management (CC&L)’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-52
Closed -$486K – 1234
2021
Q3 		$486K Buy
+52
New +$447K ﹤0.01% 774

Other funds holding SEEL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SEEL Position: Q4 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2021, closing a stake of 52 shares — an estimated $486K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SEEL in Q3 2021 and held it in 1 quarter. The position peaked at $486K in Q3 2021. 82 funds tracked by Wall St. Rank hold SEEL as of Q4 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 52 Seelos Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $486K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Seelos Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Seelos Therapeutics, Inc. Common Stock position peaked at $486K in Q3 2021.
  • 82 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2021, filed 10 Feb 2022.